CD19 and neoplasm: They demonstrated that 48.6% of engineered T cells with TCR knockout (CD3-) express CD19-CAR and that these modified cells were functionally active in vitro with regard to antigen specific proliferation, cytolytic activity and release of cytokines, and exhibited potent antitumor responses to CD19-expressing tumor cells in vivo [170].